Original ArticleSteady-State Pharmacokinetics and Tolerability of Indinavir-Lopinavir/R Combination Therapy in Antiretroviral-Experienced PatientsAntoniou, Tony*; Tseng, Alice L†‡; van Heeswijk, Rolf P G§; Walker, Scott E†∥; Giguere, Pierre§; Phillips, Elizabeth J#Author Information From *St. Michael's Hospital, Toronto, Ontario, Canada; †University of Toronto, Toronto, Ontario, Canada; ‡University Health Network, Toronto, Ontario, Canada; §Ottawa Hospital, Ottawa, Ontario, Canada; ∥Sunnybrook and Women's Health Sciences Centre, Toronto, Ontario, Canada; and #British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Received for publication April 29, 2005; accepted July 5, 2005. Supported by an unrestricted grant from Merck Frosst Canada Ltd. Reprints: Tony Antoniou, PharmD, 410 Sherbourne Street, 4th Floor, Toronto, Ontario M4X 1K2, Canada (e-mail: [email protected]). Therapeutic Drug Monitoring: December 2005 - Volume 27 - Issue 6 - p 779-781 doi: 10.1097/01.ftd.0000177665.34845.fa Buy Metrics Abstract Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis. The AUC0-12h of indinavir when combined with lopinavir/ritonavir was comparable with previously published data on indinavir/ritonavir 800/100 mg twice per day in HIV-infected individuals. However, lopinavir AUC0-12h, Cmax, and C12h were lower than previously reported in the absence of indinavir. The regimen was well tolerated, although 2 patients developed grade 3 hypertriglyceridemia. No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary. © 2005 Lippincott Williams & Wilkins, Inc.